Many people want to lose fat—especially stubborn belly and visceral fat—without the strong appetite suppression or gastrointestinal side effects of GLP-1 drugs like semaglutide or tirzepatide. 5-Amino-1MQ, AOD-9604, and Tesamorelin form a research-based non-GLP stack focused on cellular fat metabolism, direct lipolysis, and targeted visceral fat reduction. This approach aims for body recomposition (fat loss while preserving or supporting muscle) mainly through metabolic shifts rather than eating less. No large human trials test the full combination, but individual primary studies show complementary mechanisms. This article uses peer-reviewed preclinical and clinical data.
What Are These Compounds?
- 5-Amino-1MQ is a small molecule (not a peptide) that inhibits NNMT (nicotinamide N-methyltransferase), an enzyme linked to fat storage and slower metabolism. Blocking it helps preserve NAD+ and SAM, supporting better energy use and reduced fat cell expansion.
- AOD-9604 is a 16-amino-acid fragment of human growth hormone designed for fat breakdown (lipolysis) without raising IGF-1 or affecting blood sugar.
- Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates natural GH pulses, especially effective at reducing deep visceral (abdominal) fat.
The stack idea: 5-Amino-1MQ shifts fat cells toward burning rather than storing, AOD-9604 mobilizes stored fat, and Tesamorelin (optional add-on) targets stubborn visceral fat via GH pathways—ideal for recomposition without heavy hunger control.
5-Amino-1MQ: Metabolic Switch for Fat Cell Shrinkage
5-Amino-1MQ blocks NNMT, which is overactive in obese fat tissue and drains cellular energy resources. In diet-induced obese (DIO) mice, 11 days of treatment caused ~5% body weight loss (vs. slight gain in controls) and ~35% reduction in white adipose tissue mass, with smaller fat cells and lower cholesterol—without reduced food intake.
A follow-up study combining it with a low-fat diet switch produced dramatic fat loss and normalized body composition faster than diet change alone. It supports mitochondrial function and may preserve muscle during fat loss. Human clinical data is still early (emerging Phase 1 activity as of 2026), with no large efficacy trials yet published.
AOD-9604: Direct Fat Mobilization
AOD-9604 promotes lipolysis in fat cells. Human trials (hundreds of participants) confirmed safety with no major IGF-1 or glucose changes. Early studies showed modest extra weight loss (2–3 kg over placebo in some 12-week trials), though larger diet-controlled studies had mixed overall results. It may particularly help with stubborn fat areas.
Tesamorelin: Proven Visceral Fat Reducer
In two large Phase 3 trials (HIV patients with excess belly fat), 2 mg daily for 26 weeks reduced visceral adipose tissue (VAT) by ~15% (vs. little change or increase with placebo). It improved lipids and waist size while mostly sparing subcutaneous fat. Benefits were sustained in extensions.
Why This Stack? Potential Synergy for Stubborn Fat and Recomposition
- 5-Amino-1MQ rewires fat cell metabolism (less storage, more burning) at the enzyme level.
- AOD-9604 directly mobilizes stored fat for energy.
- Tesamorelin (add-on) boosts natural GH to preferentially shrink deep abdominal fat.
Together they target multiple fat-loss pathways without strong appetite suppression—great for people who eat in a moderate deficit or maintain calories while training. The focus is on body recomposition: reducing fat mass (especially stubborn/visceral) while supporting metabolic health and muscle preservation. Direct combo trials are absent, but mechanisms align well for non-GLP protocols.
Important Caveats from the Science
Tesamorelin has the strongest human evidence (FDA-approved for HIV-related visceral fat). AOD-9604 is safe in trials with modest effects. 5-Amino-1MQ shows impressive results in obese mice but human data remains limited/preliminary. None are FDA-approved for general weight loss or recomposition. Long-term safety of the stack is unknown, and compounded product quality varies. Side effects are generally mild (possible injection reactions), but these are research compounds. Best results require diet, resistance training, and medical supervision. Always consult a doctor.
The Bottom Line
Primary studies show 5-Amino-1MQ inhibits NNMT to promote fat cell shrinkage and metabolic efficiency in animal models, AOD-9604 supports direct fat mobilization with good human safety data, and Tesamorelin reliably reduces visceral fat in Phase 3 trials. As a non-GLP-1 stack, they offer a promising option for stubborn fat reduction and body recomposition through cellular and hormonal pathways rather than appetite control. Exciting area of metabolic research, but larger human trials on the full combination are still needed. Science continues developing tools for sustainable fat loss and healthier body composition.
This information is not medical advice. Results vary by individual, and these compounds should be used only under the supervision of a qualified healthcare provider with appropriate monitoring (including regular bloodwork). They are not substitutes for a healthy diet, exercise, sleep, or standard medical care. Always consult your doctor before starting any peptide or compounded regimen.
